The Patient Assistance solutions ensure patients receive their medications, even if alternative funding is unavailable or they don’t qualify for need-based assistance.
The Sandoz investment is expected to be at least $400 million, supporting the company’s ambition to drive the future growth of its global biosimilars portfolio.
Lenalidomide capsules are used in adults for treating multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes and mantle cell lymphoma following specific prior treatment.
Teriflunomide tablets are indicated for treating relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in adults.
